We are honored to have been part of the 1st Medical Symposium on Psychedelic Assisted Therapy in Mexico, dedicated to advancing psychodelic-assisted therapy for PTSD, treatment-resistant depression, and addiction through science, research, and clinical expertise.
We spoke alongside pioneers like Rick Doblin, founder of Multidisciplinary Association for Psychedelic Studies (MAPS), who shared insights on the future of psychodelic therapy, Bessel van der Kolk, trauma researcher and author of The Body Keeps the Score, and Ron Siegel, Harvard University psychologist specializing in mindfulness-based trauma therapy.
We were also deeply honored to hear from indigenous leaders, who emphasized reciprocity and ethical engagement with these medicines. Alongside many scientists, clinicians, and thought leaders, we explored the growing evidence supporting psychedelic medicine.
A huge thanks to the organizers, speakers, partners, and participants for fostering such an inspiring space for collaboration. These conversations are shaping the future of mental health, addiction treatment, and trauma recovery, and we’re grateful to be part of this movement.
At Beond, we shared insights from our clinical experience and research. Our panel explored ibogaine’s role in easing withdrawal, supporting deep healing, and promoting neurogenesis.
CEO Tom Feegel introduced Beond’s approach, Dr. Sola explained ibogaine’s neurological impact, and Research Director Shirley Cheung presented findings on its effects on alcohol and kratom dependency + traumatic brain injury case study.
Our Cofounder Talia Eisenberg also interviewed a Beond alumni and Mexican professional athlete, who shared how ibogaine supported her healing and performance.
This symposium was a powerful step toward advancing science, safety, and access to psychodelic medicine. The conversations happening here are shaping the future, and we’re excited and hopeful to be part of it. Onward.
